| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | Neoadjuvant Cemiplimab | Stage II to IV Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | Libtayo (cemiplimab) | Stage II to IV resectable cutaneous squamous cell carcinoma (CSCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | REGN5381 | Hearth failure | Phase 2 | Enrollment Initiation | Intravenous | Cardiology |
| Regeneron Pharmaceuticals Inc. | Ateganosine (THIO-101) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| Regeneron Pharmaceuticals Inc. | Vidutolimod and Libtayo (cemiplimab) | Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Ongoing | Intratumoral and intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | Vidutolimod (CMP-001) and KEYTRUDA (pembrolizumab) | Head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Ongoing | Vidutolimod intratumoral KEYTRUDA intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | Vidutolimod (CMP-001) and OPDIVO (nivolumab) | Melanoma | Phase 2 | Ongoing | Intratumoral and intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | Vidutolimod (CMP-001) and KEYTRUDA (pembrolizumab) | Melanoma | Phase 2 | Ongoing | Vidutolimod intratumoral KEYTRUDA intravenous | Oncology |